Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 8:30 AM PT / 11:30 AM ET. Interested individuals can access a live and archived webcast on Pulmonx's website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, particularly its Zephyr® Endobronchial Valve, which received FDA pre-market approval as a breakthrough device. The Zephyr Valve is available in over 25 countries and has been used in more than 20,000 patients.

REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41^st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT / 11:30am ET.

Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

What is the date and time of Pulmonx's participation in the Canaccord Genuity conference?

Pulmonx will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 8:30 AM PT / 11:30 AM ET.

Where can I find the webcast for Pulmonx's conference participation?

The live and archived webcast of Pulmonx's conference participation can be accessed on the Investors section of their website.

What is the significance of Pulmonx's Zephyr Valve?

The Zephyr Valve is a minimally invasive treatment for severe emphysema/COPD and received FDA pre-market approval as a breakthrough device.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is commercially available in over 25 countries.

How many patients have been treated with the Zephyr Valve?

The Zephyr Valve has been used to treat more than 20,000 patients.